United States· US:59310-610_a509df2c-67b6-40c3-8b6d-f9de54b62c8a
CINQAIR
A reslizumab product containing reslizumab, registered in United States by Teva Respiratory, LLC. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Reslizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DX08 (reslizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Reslizumab · ATC R03DX08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RESLIZUMAB
- Manufacturer
- Teva Respiratory, LLC
- Country
- United States (US)
- ATC code
- R03DX08
- ATC class
- Reslizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1159310-610-31
- ndc1159310610311 VIAL, SINGLE-USE in 1 CARTON (59310-610-31) / 10 mL in 1 VIAL, SINGLE-USE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- FinlandCINQAEROTeva B.V.
- BelgiumCinqaero 10 mg/mlTeva
- SwedenCINQAERO 10 mg/ml Koncentrat till infusionsvätska, lösningTeva B.V.
- IrelandCINQAERO 10 mg/mL concentrate for solution for infusionTeva B.V.
- IcelandCinqaeroTeva B.V.*
- PolandCinqaeroTeva B.V.
- SwitzerlandCinqaero 100 mg/10 mL, Konzentrat zur Herstellung einer InfusionslösungTeva Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Cinqaero
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2a2c0b54-f1d8-43e3-aea1-d79fa640722e GET /v1/drugs/2a2c0b54-f1d8-43e3-aea1-d79fa640722e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "10",
"substance": "RESLIZUMAB",
"productndc": "59310-610",
"dosage_form": "INJECTION, SOLUTION, CONCENTRATE",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761033",
"marketing_category": "BLA"
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.